ارتباط پلی‌مورفیسم rs6065668 و بیان ژن TOX2 با خطر ابتلا به سرطان کولورکتال

نوع مقاله : Original Article(s)

نویسندگان

1 فوق لیسانس، گروه علوم، دانشکده‌ی علوم پایه، واحد دزفول، دانشگاه آزاد اسلامی، دزفول، ایران

2 استادیار، گروه پرستاری و مامایی، واحد دزفول، دانشگاه آزاد اسلامی، دزفول، ایران

3 استادیار، گروه ژنتیک و بیولوژی مولکولی، دانشکده‌ی پزشکی، دانشگاه علوم پزشکی دزفول، دزفول، ایران

چکیده

مقاله پژوهشی




مقدمه: سرطان کولورکتال (Colorectal cancer) CRC، سومین سرطان شایع و چهارمین علت مرگ در اثر سرطان محسوب می‌شود. چندین ژن با نفوذ متفاوت و همچنین واریانت‌های مختلف ژنتیکی برای خطر ابتلا به CRC شناسایی شده است. بر اساس مطالعات، ژن TOX2 به عنوان ژن کاندید درCRC مطرح می‌باشد. در مطالعه‌ی حاضر، ارتباط پلی‌مورفیسم rs6065668 و بیان ژن TOX2 با خطر ابتلا به CRC بررسی شد.
روش‌ها: در مطالعه‌ی حاضر، 2 سی‌سی خون وریدی از 50 نفر بیمار مراجعه‌کننده به مرکز درمانی سرطان امام حسن مجتبی (ع) دزفول و 50 فرد سالم به عنوان گروه شاهد (همسان‌سازی شده از نظر سن و جنس) جمع‌آوری گردید. در این مطالعه پلی‌مورفیسم rs6065668 ژن TOX2 با تکنیک (High Resolution Melting) HRM و بیان ژن بوسیله‌ی‌ تکنیک Real-time PCR مورد بررسی قرار گرفت.
یافته‌ها: فراوانی ژنوتیپ‌ها در بیماران 42 درصد برای ژنوتیپ CC، 46 درصد برای CT و 12 درصد برای TT بود و در گروه شاهد برای ژنوتیپ‌هایCC، CT و TT  به ترتیب 26، 54 و 20 درصد بود که تفاوت معنی‌داری بین گروه‌ها نشان نداد و نتایج بیان ژن نیز در بین گروه‌ها و در ژنوتیپ‌های مختلف تفاوت معنی‌داری نداشت.
نتیجه‌گیری: با توجه به اینکه فراوانی ژنوتیپ‌های TT، CT،  CCو همچنین بیان ژن TOX2 از لحاظ آماری تفاوت معنی‌داری بین افراد CRC در مقایسه با افراد سالم نشان ندادند، بنابراین نتایج مطالعه‌ی حاضر نشان داد که تغییرات در ژن TOX2 با خطر ابتلا به CRC مرتبط نمی‌باشد.

کلیدواژه‌ها

موضوعات

عنوان مقاله [English]

Association of rs6065668 Polymorphism and TOX2 Gene Expression with Colorectal Cancer Risk

نویسندگان [English]

  • Forough Eidikhosh 1
  • Zohreh Valizadeh 2
  • Abbas Moridnia 3
1 MSc, Department of Science, School of Basic Sciences, Dezful Branch, Islamic Azad University, Dezful, Iran
2 Assistant Professor, Department of Nursing and Midwifery, Dezfoul Branch, Islamic Azad University, Dezfoul, Iran
3 Assistant Professor, Department of Genetics and Molecular Biology, School of Medicine, Dezful University of Medical Sciences, Dezful, Iran
چکیده [English]

Background: Colorectal cancer (CRC) is the third most common cancer and the fourth cause of death due to cancer. Several genes with different penitence, as well as different genetic variants, have been identified in CRC risk. Based on the studies, the TOX2 gene is proposed as a candidate gene for CRC. In the present study, the relationship between rs6065668 polymorphism and TOX2 gene expression was investigated with the risk of CRC.
Methods: In the present study, 2 CC of venous blood was collected from 50 patients referred to the Imam Hassan Mojtabi Cancer Treatment Center in Dezful, and 50 healthy individuals as a control group (matched in terms of age and gender). In this study, rs6065668 polymorphism of the TOX2 gene was investigated by the High-Resolution Melting (HRM) technique and gene expression by the Real-time PCR method.
Findings: Findings: The frequency of genotypes in patients was 42% for the CC genotype, 46% for CT, and 12% for TT, and in the control group, CC, CT, and TT genotypes were 26%, 54%, and 20%, respectively, which had no significant difference between the groups and as well as the results of gene expression were not significantly different between groups and different genotypes.
Conclusion: Considering that the frequency of CC, CT, and TT genotypes as well as TOX2 gene expression did not show a statistically significant difference between CRC patients compared to healthy subjects, the results of this study showed that changes in TOX2 gene are not related to the risk of CRC.

کلیدواژه‌ها [English]

  • Colorectal cancer
  • TOX2
  • Genotype
  • Polymorphism

مراجع

  1. Sabouri S, Esmaily H, Shahid Sales S, Emadi M. Determining related factors to survival of colorectal cancer patients using cox regression [in Persian]. Med J Mashhad Univ Med Sci 2018; 61(4): 1083-92.
  2. Global Burden of Disease Cancer Collaboration, Fitzmaurice C, Akinyemiju TF, Al Lami FH, Alam T, Alizadeh-Navaei R, et al. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2016: a systematic analysis for the global burden of disease study. JAMA Oncol 2018; 4(11): 1553-68.
  3. Rychter AM, Łykowska-Szuber L, Zawada A, Szymczak-Tomczak A, Ratajczak AE, Skoracka K, et al. Why does obesity as an inflammatory condition predispose to colorectal cancer? J Clin Med 2023; 12(7): 2451.
  4. Jones WF, Ahnen DJ, Schroy 3rd Improving on-time colorectal cancer screening through lead time messaging. Cancer 2020; 126(2): 247-52.
  5. Hirata M, Kamatani Y, Nagai A, Kiyohara Y, Ninomiya T, Tamakoshi A, et al. Cross-sectional analysis of BioBank Japan clinical data: a large cohort of 200,000 patients with 47 common diseases. J Epidemiol 2017; 27(3S): S9-21.
  6. Tanikawa C, Kamatani Y, Takahashi A, Momozawa Y, Leveque K, Nagayama S, et al. GWAS identifies two novel colorectal cancer loci at 16q24.1 and 20q13.12. Carcinogenesis 2018; 39(5): 652-60.
  7. Cui R, Okada Y, Jang SG, Ku J, Park JG, Kamatani Y, et al. Common variant in 6q26-q27 is associated with distal colon cancer in an Asian population. Gut 2011; 60(6): 799-805.
  8. Dunlop MG, Dobbins SE, Farrington SM, Jones AM, Palles C, Whiffin N, et al. Common variation near CDKN1A, POLD3 and SHROOM2 influences colorectal cancer risk. Nat Genet 2012; 44(7): 770-6.
  9. Palles C, Cazier JB, Howarth KM, Domingo E, Jones AM, Broderick P, et al. Germline mutations affecting the proofreading domains of POLE and POLD1 predispose to colorectal adenomas and carcinomas. Nat Genet 2013; 45(2): 136-44.
  10. Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature 2012; 487(7407): 330-7.
  11. Law PJ, Timofeeva M, Fernandez-Rozadilla C, Broderick P, Studd J, Fernandez-Tajes J, et al. Association analyses identify 31 new risk loci for colorectal cancer susceptibility. Nat Commun 2019; 10(1): 2154.
  12. Yuan Y, Bao J, Chen Z, Villanueva AD, Wen W, Wang F, et al. Multi-omics analysis to identify susceptibility genes for colorectal cancer. Hum Mol Genet 2021; 30(5): 321-30.
  13. Aliahmad P, De La Torre B, Kaye J. Shared dependence on the DNA-binding factor TOX for the development of lymphoid tissue-inducer cell and NK cell lineages. Nat Immunol 2010; 11(10): 945-52.
  14. Bi J, Wang X. Molecular regulation of NK cell maturation. Front Immunol 2020; 11: 1945.
  15. Vong QP, Leung WH, Houston J, Li Y, Rooney B, Holladay M, et al. TOX2 regulates human natural killer cell development by controlling T-BET expression. Blood 2014; 124(26): 3905-13.
  16. Tessema M, Yingling CM, Grimes MJ, Thomas CL, Liu Y, Leng S, et al. Differential epigenetic regulation of TOX subfamily high mobility group box genes in lung and breast cancers. PloS One 2012; 7(4): e34850.
  17. Zeng Y, Navarro P, Shirali M, Howard DM, Adams MJ, Hall LS, et al. Genome-wide regional heritability mapping identifies a locus within the TOX2 gene associated with major depressive disorder. Biol Psychiatry 2017; 82(5): 312-21.
  18. Kajitani T, Mizutani T, Yamada K, Yazawa T, Sekiguchi T, Yoshino M, et al. Cloning and characterization of granulosa cell high-mobility group (HMG)-box protein-1, a novel HMG-box transcriptional regulator strongly expressed in rat ovarian granulosa cells. Endocrinology 2004; 145(5): 2307-18.
  19. Bigdeli TB, Maher BS, Zhao Z, van den Oord EJ, Thiselton DL, Sun J, et al. Comprehensive gene-based association study of a chromosome 20 linked
    region implicates novel risk loci for depressive symptoms in psychotic illness. PloS One 2011; 6(12): e21440.
  20. Fanous AH, Neale MC, Webb BT, Straub RE, O'Neill FA, Walsh D, et al. Novel linkage to chromosome 20p using latent classes of psychotic illness in 270 Irish high-density families. Biol Psychiatry 2008; 64(2): 121-7.
  21. Sima C, Iordache P, Poenaru E, Manolescu A, Poenaru C, Jinga V. Genome-wide association study of nephrolithiasis in an Eastern European population. Int Urol Nephrol 2021; 53(2): 309-13
  22. .O'Flaherty E, Kaye J. TOX defines a conserved subfamily of HMG-box proteins. B BMC Genomics 2003; 4(1): 1-10.
  23. Seo H, Chen J, González-Avalos E, Samaniego-Castruita D, Das A, Wang YH, et al. TOX and TOX2 transcription factors cooperate with NR4A transcription factors to impose CD8+ T cell exhaustion. Proc Natl Acad Sci U S A 2019; 116(25): 12410-5.
مجله دانشکده پزشکی اصفهان
دوره 41، شماره 725
هفته 1، شهریور
مرداد و شهریور 1402
صفحه 517-523

فایل ها

سابقه مقاله

  • تاریخ دریافت: 14 تیر 1402
  • تاریخ پذیرش: 07 مرداد 1402

هم رسانی

ارجاع به این مقاله

آمار